Pharmacist-Led Strategies to Improve Identification and Uptake of CDK4/6 Inhibitors in Breast Cancer

In Pharmacist-Led Strategies to Improve Identification and Uptake of CDK4/6 Inhibitors in Breast Cance, our panel delves into the following critical questions:

How are pharmacists identifying patients who are eligible for CDK4/6 inhibitors and how are you best communicating this to providers?

How can pharmacists get patients and providers to buy into these therapies?

Led by Rose DiMarco, PharmD, the breast cancer panelists discuss pharmacists playing a critical role in identifying patients who are eligible for CDK4/6 inhibitors in the early breast cancer setting by reviewing medical records, assessing risk factors, and monitoring adherence to guideline-recommended criteria. They often collaborate closely with oncologists and care teams to ensure eligible patients are considered for therapy and that any potential barriers to treatment are addressed. Communication with providers is key, and pharmacists have found that presenting clear, evidence-based summaries of trial data—along with individualized patient risk profiles—can help facilitate informed discussions. Faculty highlighted strategies to encourage both patients and providers to buy into these therapies, including patient education, shared decision-making, and emphasizing the long-term survival benefits observed in clinical trials. Despite this, CDK4/6 inhibitors remain underutilized, with studies indicating that on

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, CDK4/6 Inhibitors in Metastatic Breast Cancer: Approvals and Clinical Considerations, further explores the FDA-approved CDK4/6 inhibitors for metastatic breast cancer and the pivotal clinical trials that supported their regulatory approval. Faculty also discuss the use of these agents in patients with visceral crisis, including available evidence and clinical considerations for this high-risk population.